A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
Bert H. O'Neil,J. Wallmark,David Lorente,Elena Elez,J. Raimbourg,Carlos Gomez-Roca,Samuel Ejadi,Sarina Anne Piha-Paul,R.A. Moss,Lillian L. Siu,K. Dotti,Armando Santoro,M. Gould,S.S. Yuan,Minori Koshiji,Sae-Won Han +15 more
Journal ArticleDOI
New technology and changing parameters of leukapheresis for blood cell transplantation.
TL;DR: The role of phospholipids in thrombosis after treatment of diffuse large cell non Hodgkin’s lymphoma and concomitant lupus anticoagulant is investigated.
Journal ArticleDOI
Thrombin generation predicts early recurrence in breast cancer patients.
Marina Marchetti,Cinzia Giaccherini,Giovanna Masci,Cristina Verzeroli,Laura Russo,Luigi Celio,Roberta Sarmiento,Sara Gamba,Carmen J Tartari,Erika Diani,Alfonso Vignoli,Paolo Malighetti,Daniele Spinelli,N. M. Kuderer,Federico Nichetti,Mauro Minelli,Carlo Tondini,Sandro Barni,Francesco Giuliani,Fausto Petrelli,Andrea D'Alessio,Giampietro Gasparini,Roberto Labianca,Armando Santoro,Filippo de Braud,Anna Falanga +25 more
TL;DR: Cancer patients present with a hypercoagulable state often associated with poor disease prognosis and are likely to have a low likelihood of survival in the clinic.
Journal ArticleDOI
Herpes infections in breast cancer patients treated with adjuvant chemotherapy.
Giovanna Masci,Massimo Magagnoli,Giuseppe Gullo,Emanuela Morenghi,I. Garassino,Matteo Simonelli,Armando Santoro +6 more
TL;DR: The findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection and the risk of developing herpes zoster in breast cancer patients may be 13- to 25-fold higher compared to the incidence in the general population.
Journal ArticleDOI
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
Lorenza Rimassa,Camillo Porta,Ivan Borbath,Bruno Daniele,Richard S. Finn,Jean-Luc Raoul,Lawrence H. Schwartz,Aiwu Ruth He,Joerg Trojan,Markus Peck-Radosavljevic,Giovanni Abbadessa,Terri Goldberg,Armando Santoro,Jordi Bruix +13 more
TL;DR: This randomized, double-blind study will investigate tivantinib monotherapy as second-line treatment in patients with advanced, pretreated, MET-high HCC, and will provide the first effective therapy for a biologically selected patient population in HCC.